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Background: The baseline susceptibility of primary 
HIV-2 to maraviroc (MVC) and other entry inhibitors is 
currently unknown.
Methods: The susceptibility of 19 HIV-2 isolates obtained 
from asymptomatic and AIDS patients and seven HIV-1 
clinical isolates to the fusion inhibitors enfuvirtide (ENF) 
and T-1249, and to the coreceptor antagonists AMD3100, 
TAK-779 and MVC, was measured using a TZM-bl cell-
based assay. The 50% inhibitory concentration (IC50), 90% 
inhibitory concentration (IC90) and dose–response curve 
slopes were determined for each drug.
Results: ENF and T-1249 were significantly less active 
on HIV-2 than on HIV-1 (211- and 2-fold, respectively). 
AMD3100 and TAK-779 inhibited HIV-2 and HIV-1 CXCR4 
tropic (X4) and CCR5 tropic (R5) variants with similar IC50 
and IC90 values. MVC, however, inhibited the replication 
of R5 HIV-2 variants with significantly higher IC90 values 
(42.7 versus 9.7 nM; P<0.0001) and lower slope values 
(0.7 versus 1.3; P<0.0001) than HIV-1. HIV-2 R5 variants 
derived from AIDS patients were significantly less sensi-
tive to MVC than variants from asymptomatic patients, 
this being inversely correlated with the absolute number 
of CD4+ T-cells.
Conclusions: T-1249 is a potent inhibitor of HIV-2 repli-
cation indicating that new fusion inhibitors might be use-
ful to treat HIV-2 infection. Coreceptor antagonists TAK-
779 and AMD3100 are also potent inhibitors of HIV-2 
replication. The reduced sensitivity of R5 variants to MVC, 
especially in severely immunodeficient patients, indicates 
that the treatment of HIV-2-infected patients with MVC 
might require higher dosages than those used in HIV-1 
patients, and should be adjusted to the disease stage.
HIV-2 affects an estimated 1–2 million individuals world-
wide and leads to AIDS and death, albeit at a slower pace 
when compared to HIV-1. All currently available anti-
retroviral drugs were specifically designed to inhibit HIV-1 
entry and replication. Consequently, some drug classes are 
not active on HIV-2 (that is, non-nucleoside reverse tran-
scriptase and fusion inhibitors) and virological and immu-
nological responses to treatment regimens incorporating 
active drugs are usually poorer in HIV-2 patients [1].
The envelope glycoproteins of HIV-1 and HIV-2 are 
markedly different at the amino acid sequence level and 
at the structural and functional levels. In contrast to HIV-
1, HIV-2 may enter cells without binding to CD4, and 
by using multiple alternative coreceptors besides CCR5 
and CXCR4 [2,3]. This suggests that maraviroc (MVC), a 
CCR5 antagonist, might also have limited activity against 
HIV-2. Currently, there is no information concerning the 
in vitro susceptibility of HIV-2 primary isolates to MVC, 
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enfuvirtide (ENF) or any other entry inhibitor. In the 
absence of formal clinical trials, in vitro evaluation of the 
baseline susceptibility of HIV-2 primary isolates to MVC 
is crucial to assess the potential clinical value of this drug 
in HIV-2 therapy [4]. Here we have analysed the suscep-
tibility of HIV-2 primary isolates obtained from asymp-
tomatic and AIDS patients to the fusion inhibitors ENF 
and T-1249 and to the coreceptor antagonists AMD3100, 
TAK-779 and MVC.
Methods
Primary isolates were obtained from HIV-2-infected 
Portuguese patients and, for comparison, from HIV-
1- infected Angolan patients, all naive to therapy 
with entry inhibitors, by cocultivation with periph-
eral blood mononuclear cells from seronegative sub-
jects (Table  1) [5]. Virus genotyping was performed 
by phylogenetic analysis using C2-V3-C3 (HIV-2) 
or gp41 (HIV-1) env sequences. GenBank accession 
numbers for newly derived sequences are HQ738345–
HQ738350 for HIV-2 and HQ738338–HQ738344 
for HIV-1. 
CCR5 and CXCR4 tropism was determined using 
a single-round viral infectivity assay performed with 
TZM-bl reporter cells (CD4+, CCR5+ and CXCR4+) in 
the presence of excessive amounts of the CCR5 antago-
nist TAK-779 (10 mM) and/or of the CXCR4 antagonist 
AMD3100 (1.2 mM), as previously described [6]. The 
50% inhibitory concentration (IC50), 90% inhibitory 
concentration (IC90) and dose–response curve slopes 
(Hill slopes) of ENF and T-1249 (fusion inhibitors) and 
AMD3100, TAK-779 and MVC (coreceptor antago-
nists) were determined on the newly derived panel of 
isolates (200× 50% tissue culture infective dose for each 
virus) using also the TZM-bl reporter cell assay. IC50, 
IC90 and Hill slopes were estimated by the sigmoidal 
dose–response (variable slope) equation in Prism ver-
sion 4.0c for Macintosh (GrahPad Software, San Diego, 
CA, USA). Prism was also used for statistical analyses 
(P-value <0.05). 
Results
Genotypic and phenotypic characterization of virus 
isolates
A total of 19  new HIV-2 primary isolates were used 
in this study, all belonging to group A (Table 1 and 
Additional file 1). Overall, 10 were CCR5 tropic (R5 
isolates), 8 CXCR4 tropic (X4 isolates) and 1 used 
both coreceptors (dual/mixed population). The seven 
new HIV-1 primary isolates were all R5 and their 
genotypes were distributed as follows: subtype G (1 
isolate), J (2 isolates) and CRF02_AG (1 isolate); 3 
isolates were untypable (Table 1 and Additional file 2).
Antiviral activity of coreceptor antagonists
AMD3100 and TAK-779 inhibited the replication of 
HIV-1 and HIV-2 with similar IC50, IC90 and slope val-
ues (Tables 1 and 2). MVC also inhibited the replication 
of HIV-2 and HIV-1 R5 variants with similar IC50 val-
ues (Table 1); for HIV-1, the IC50s were similar to previ-
ously reported values (range 0.1–4.5 nM; Table 1) [7]. 
However, MVC inhibited the replication of R5 HIV-2 
variants with significantly higher IC90 values (42.7 ver-
sus 9.7 nM; P<0.0001) and lower slope values (0.7 ver-
sus 1.3; P<0.0001) than HIV-1 (Figure 1A and Table 
2). R5 variants isolated from HIV-1 patients after AIDS 
diagnosis have reduced sensitivity to TAK-779 as com-
pared to R5 variants isolated at the asymptomatic stage 
[8,9]. Strikingly, we also found a strong and significant 
negative correlation between HIV-2 sensitivity to MVC 
(as determined by the IC50s) and CD4
+ T-cell counts 
at the time of virus isolation (Spearman’s r=-0.831; 
P=0.008; Figure 1B). Consistent with this, isolates from 
AIDS patients were significantly less sensitive to MVC 
(that is, their IC50s were significantly higher) than iso-
lates from asymptomatic patients (Figure 1C). A similar 
tendency was observed for TAK-779 (Additional file 3). 
In all, these results demonstrate that HIV-2 R5 variants 
have lower sensitivity to MVC than HIV-1 and suggest 
that resistance of these variants to MVC increases as 
disease progresses [8,9].
Antiviral activity of fusion inhibitors
In this study, ENF was 211-fold less active against pri-
mary isolates of HIV-2 than against HIV-1 (mean IC50 
281.5 versus 1.2 nM; P<0.0001; Figure 1D and Table 
2), confirming and extending previous results based on 
lab adapted isolates [10]. Interestingly, with one excep-
tion, all HIV-1 primary isolates exhibited high sensi-
tivity to ENF (Table  1). Sequencing analysis showed 
that these isolates carried the N42S polymorphism in 
the gp41 glycoprotein, whereas the less sensitive strain 
did not (data not shown). This polymorphism, which is 
more prevalent in several non-B subtypes and recom-
binant forms than in subtype B, has previously been 
associated with higher sensitivity to ENF both in B and 
non-B HIV-1 subtypes [11].
In contrast to ENF, T-1249 was active on HIV-2, 
although at higher concentrations than on HIV-1 (IC50 
4.3 versus 2.0 nM; P<0.0001). Moreover, T-1249 was 
more active on X4 than on R5 isolates both in HIV-1 
(IC50 0.6 versus 2.9 nM; P<0.0001) and HIV-2 (IC50 
3.2 versus 6.1 nM; P=0.0005).
Discussion
We have demonstrated that MVC inhibits the repli-
cation of R5 HIV-2 variants with significantly higher 
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IC90s and lower slope values than HIV-1 indicating that 
higher dosages of MVC might be required for the treat-
ment of HIV-2-infected patients [12,13]. So far, MVC 
use in HIV-2 infection was reported on only two occa-
sions with uncertain results [14,15]. Clinical trials are 
therefore needed to determine if the MVC dosages 
recommended in HIV-1 infection are also effective for 
HIV-2 infection. This may prevent the administration 
of subtherapeutic dosages that favour the selection of 
X4 variants which, in HIV-2, have been associated not 
only with CD4 depletion and disease progression [2], 
but also with resistance to neutralization [16].
Similarly to previous results obtained with RANTES 
for HIV-2 [17] and with TAK-779 and C-C chemokines 
for HIV-1 [8,9], MVC inhibits the replication of R5 
HIV-2 variants isolated from AIDS patients with sig-
nificantly higher IC50s than R5 variants isolated from 
asymptomatic patients, this being inversely associated 
with the number of CD4+ T-cells. In HIV-2-infected 
patients, CD4 depletion and higher immune activation 
are also closely associated with an increased frequency 
of memory CD4+ T-cells expressing CCR5, the prefer-
ential target cells of this virus [18]. Hence, these results 
suggest that in HIV-2-infected patients MVC dosage 
may need to be adjusted according to the number of 
CD4+ T-cells (higher dosage in severely immunode-
ficient patients and lower dosage in asymptomatic 
patients). Increased MVC resistance of late stage dis-
ease R5 variants might be explained by increased affin-
ity for CCR5 [19] and/or an enhanced viral infectivity 
and replicative capacity [8,19]. Alternatively, these R5 
variants may be evolutionary intermediates toward X4 
use [8,17].
The reduced activity of ENF on primary HIV-2 
isolates provides definitive evidence that ENF is not 
useful for HIV-2 therapy. The low activity of ENF in 
HIV-2 is probably related to the high genetic vari-
ability between HIV-1 and HIV-2 in the HR1 and 
HR2 domains in the gp41 glycoprotein [10,20]. By 
contrast, T-1249, a second-generation fusion inhibi-
tor available only for research use was highly active 
on both HIV-1 and HIV-2 indicating that new fusion 
inhibitors (peptides or small-molecules) might be use-
ful to treat HIV-2 infection.
In summary, primary isolates of HIV-1 and HIV-2 
with X4 or R5 tropism have similar sensitivities to 
AMD3100 and TAK-779, respectively. However, sig-
nificantly higher IC90s of MVC are required to inhibit 
Parametera HIV‑1 HIV‑2b P‑valuec
AMD3100  – – –
Patients, n 2 9 –
IC50, nM 2.1 (1.1, 3.8) 2.6 (2.2, 3.0) 0.288
IC90, nM 16.7 (4.4, 62.8) 29.0 (20.8, 40.5) 0.213
Hill slope 1.0 (0.5, 1.6) 0.9 (0.8, 1.0) 0.391
TAK‑779  – – –
Patients, n 7 10 –
IC50, nM 23.3 (12.0, 45.4) 18.9 (11.8, 30.3) 0.595
IC90, nM 5,200.0 (1,161.4, 23,334.6) 11,587.8 (3,899.4, 34,514.4) 0.379
Hill slope 0.4 (0.3, 0.5) 0.3 (0.3, 0.4) 0.237
Maraviroc – – –
Patients, n 7 10 –
IC50, nM 1.7 (1.4, 2.2) 2.1 (1.7, 2.6) 0.201
IC90, nM 9.7 (6.6, 14.4) 42.7 (26.6, 68.4) <0.0001
Hill slope 1.3 (1, 1.6) 0.7 (0.6, 0.8) <0.0001
Enfuvirtide – – –
Patients, n 9 20 –
IC50, nM 1.2 (0.7, 2.2) 281.5 (223.2, 354.9) <0.0001
IC90, nM 95.9 (26.3, 350.8) 3,881.5 (2,393.3, 6,280.6) <0.0001
Hill slope 0.5 (0.4, 0.6) 0.8 (0.7, 1) 0.001
T‑1249 – – –
Patients, n 9 20 –
IC50, nM 2.0 (1.4, 2.8) 4.3 (3.6, 5.2) <0.0001
IC90, nM 14.3 (6.9, 29.5) 40.6 (28.1, 58.5) 0.006
Hill slope 1.1 (0.8, 1.4) 1 (0.8, 1.1) 0.426
Table 2. Comparison of antiviral activities of the different entry inhibitors on HIV‑1 and HIV‑2 primary isolates
Data are mean (95% CI). aThe 50% inhibitory concentration (IC50), the 90% inhibitory concentration (IC90) and slope best‑fit values were inferred from sigmoidal dose‑
response (variable slope) curves adjusted to combined results of HIV‑1 and HIV‑2 isolates. bEstimates for AMD3100, TAK‑779 and maraviroc did not include the HIV‑2 
10PTHSMAK isolate, a virus with dual/mixed tropism. cP‑value for comparison of best‑fit values between HIV‑1 and HIV‑2, using the F test. 
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replication of HIV-2 R5 variants than HIV-1 vari-
ants. Additionally, the sensitivity of HIV-2 R5 vari-
ants to this drug is inversely related with CD4+ T-cell 
counts at time of virus isolation. If MVC is to be used 
in HIV-2 patients, clinical trials should be performed 
to fully evaluate the clinical efficacy of this drug in 
HIV-2 infection and determine the best therapeutic 
dosage in early- and late-stage disease. Because X4 
HIV-2 variants and dual/mixed HIV-2 populations 
are totally or partially resistant to MVC, coreceptor 
tropism should be determined before initiation of 
MVC therapy in HIV-2-infected patients. To this 
end, genotypic tropism assays, possibly based on the 
sequence of the V3 loop [2], should be developed to 
facilitate tropism assignment. Once used regularly in 
HIV-2 patients, the effect of MVC in the phenotypic 
evolution of this virus in vivo should be fully inves-
tigated as MVC has the potential to select for HIV-2 
X4 variants that are associated with poor disease 
prognosis.
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Figure 1. HIV‑1 and HIV‑2 susceptibility to clinically available fusion inhibitors
Representative dose–response curves for HIV‑1 and HIV‑2 with (A) maraviroc and (B) enfuvirtide. Data points represent the mean of results obtained on HIV‑1 and HIV‑2 
isolates and bars represent the 95% CI of the mean. Sigmoidal dose–response (variable slope) curves were adjusted to these data points; dashed lines represent the 95% 
confidence band of the best‑fit curve. (C) Scatter plot of maraviroc 50% inhibitory concentrations (IC50s) with the CD4
+ T‑cell counts at the time of virus isolation in 
each HIV‑2 patient infected with a CCR5 coreceptor tropism (R5) variant. Parameters from non‑parametric correlation and linear regression analysis are shown. Isolate 
00PTHDECT was excluded from this analysis since it was isolated from a child and therefore only CD4+ T‑cell percentage and not absolute CD4+ T‑cell counts should be 
considered. (D) Distribution of maraviroc IC50 (closed circles) and 90% inhibitory concentration (IC90; open circles) values according to two arbitrary levels of CD4
+ T‑cells: 
<200 cells/ml, which is an AIDS‑defining condition, and >200 cells/ml. Isolate 00PTHDECT was also excluded from this analysis. P‑value for comparison of medians was 
determined using the non‑parametric Mann–Whitney U test. D/M, dual/mixed viral population using CCR5 and CXCR4 coreceptors; X4, CXCR4 tropism. 
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